The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding ...

Cathie Wood doubled down on Tempus AI, despite the fact that TEM stock erased most of the gains made in the past month.

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an emerging AI player in the healthcare field with a robust outlook ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

We recently published a list of 10 AI Stocks on Analysts’ Radar As AI Spending Grows. In this article, we are going to take a ...

Tempus posted a fourth-quarter adjusted net loss of $0.18 per share, $0.02 more per share than estimates by analysts surveyed by Visible Alpha. Revenue jumped 36% year-over-year to $200.7 million, but ...

Despite optimistic news from the CEO yesterday afternoon, the company's shares fell overnight and a major investment house ...

The shift follows the DeepSeek breakthrough that showed it’s possible to reduce the amount of resources needed to run large ...

TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

We recently published a list of 12 AI Updates Worth Taking a Look At. In this article, we are going to take a look at where Tempus AI, Inc.

Q4 2024 Earnings Call Transcript February 24, 2025 Tempus AI, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.15. Operator: Thank you for standing by. My name ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...